Search

everythinglearnresearchcommunity

for

Search:↓

A user is experiencing facial bloating from low-dose topical finasteride due to high estradiol levels and is seeking advice on using DIM to manage this issue, including dosage and brand recommendations.

The conversation discusses how to use fluridil/topilutamide with other hair loss treatments like liquid minoxidil and CB-03-01, considering fluridil's hydrophobic nature and potential degradation with water. The user questions the necessity of washing hair only once per week as suggested by the manufacturer.

The conversation discusses Melatonin's potential benefits for AGA and a product called "Asatex" by ASATONA AG. The company was uncooperative when contacted for purchase inquiries.

Capilia Longa is considered as an alternative to Minoxidil for beard growth, with some users reporting positive results. However, concerns exist about its effectiveness and high cost, especially for scalp use.

User asks about Eucapil (fluridil) for hair loss, its effectiveness, safety, and where to buy in Australia. Others share experiences and purchase options.

Hope Medicine's HMI-115 is expected to be released in 2027, with phase 3 trials currently recruiting. Concerns include the safety of targeting prolactin and the potential cost of the treatment.

Pyrilutamide (KX-826) is being discussed as a potential hair loss treatment, with some users reporting no regrowth after three months. It may prevent further hair loss but might not promote regrowth unless combined with Minoxidil.

User has hair loss, finasteride for 5 years not effective. Considers trying dutasteride, minoxidil, or pyrilutamide.

JXL082 is not the same as PP405, leading to a halt in sales and a plan to synthesize the real PP405. There is skepticism about the safety and effectiveness of JXL082 and PP405, with concerns about patent issues and the long-term impact on hair growth.

The user is experiencing hair loss after a hair transplant and is considering using fluridil (Eucapil) and possibly alfatradiol as treatments, as they couldn't tolerate finasteride or minoxidil. The manufacturer of Eucapil confirmed they won't produce higher concentrations due to lack of efficacy.

Considering a hair transplant, using Pyrilutamide, the potential availability of CosmeRNA, and the significance of taking Minoxidil and Finasteride for long-term results.

PP405 is likely fake, and JXL069 is an unrefined prototype with unknown side effects. It's advised to wait for the official PP405 release.

The safety of combining alfatradiol and fluridil with finasteride as a potential treatment for male pattern baldness, which is approved in the European Union. Other treatments such as minoxidil and RU58841 were also discussed.

The conversation discusses the potential role of prolactin in hair loss and mentions treatments like HMI115, mucuna pruriens, Zinc, and B6 P5P for lowering prolactin levels. It also touches on the use of natural compounds and the lack of studies due to funding issues.

The user experienced negative side effects from oral minoxidil, including cardiac issues and excessive sweating, and decided to switch to topical minoxidil while using other treatments like RU58841, Setipiprant, Azelaic acid, and latanoprost. Another user suggested splitting the oral minoxidil dose to reduce side effects.

Users discussed experiences with Everychem's solution similar to PP405 for hair loss, noting some positive results like increased hair thickness and new growth. There was skepticism about the product's legitimacy and safety, with some users reporting early signs of effectiveness and others expressing concerns about the lack of evidence and safety profiles.

Bicalutamide and spironolactone are being compared for their effectiveness and safety in treating female pattern hair loss. The conversation seeks advice on which is better to use.

Amplifica's new injectable treatment for androgenetic alopecia shows a 15% increase in hair thickness and coarseness in 60 days. The treatment is in early human trials and offers a promising alternative to hormone-related hair loss treatments.

The user plans to use 1% Koshine826, 0.1% Alfatradiol, Minoxidil with Tretinoin, microneedling, and Stemoxydine for hair loss treatment. They expect significant recovery with this regimen.

The user used finasteride but stopped due to side effects, then used topical minoxidil for 13 months, and later added KX826/pyrilutamide for 8 months. They experienced shedding after starting pyrilutamide and use minoxidil and KX826 once daily.

Be cautious when sourcing PP405 or its analogs from third-party suppliers due to potential safety risks and lack of regulatory approval. The conversation highlights concerns about counterfeit products and the absence of reliable testing, making it risky to use such treatments.

Calecim (PTT-6) Advanced Hair System is a 6-week hair restoration product using stem cell-derived ingredients to stimulate hair growth. Users are skeptical, calling it overpriced and ineffective, suggesting alternatives like LLLT devices or PRP treatments.

Capilia Longa and Scandinavian Biolabs are discussed, with skepticism about their effectiveness and value. The conversation suggests avoiding these products due to high cost and perceived lack of results.

The user experienced temple recession, shedding, and acne while on 0.5mg dutasteride, 1.25mg finasteride every other day, and 5mg oral minoxidil daily. They are considering switching treatments due to worsening symptoms and are contemplating using a topical anti-androgen like RU58841.

The user tried minoxidil 5% for 3 years with little improvement, then switched to a 15% minoxidil with 0.1% finasteride solution once daily and started using pyrilutamide, resulting in significant hair regrowth over time. They are considering a hair transplant but are continuing with topical treatments to maximize hair growth first.

Pelage Pharmaceuticals received $120 million in Series B funding for hair loss treatment development. The conversation expresses excitement and anticipation for the release and effectiveness of the treatment.

Pelage Pharmaceuticals is developing PP405, a topical treatment for hair growth, currently in Phase 2a trials. There is skepticism about the company's claims, and no fast-tracking approval timeline has been detailed.

Using DIM and Calcium D-Glucarate to reduce finasteride side effects. Discussion includes dosage, brand, and product effectiveness.

A satirical post humorously discusses a fictional hair regrowth drug called PP405, with users joking about its effectiveness and bizarre presentation. The conversation includes humorous reactions and references to the absurdity of the content.

The conversation is about finding the optimal concentration of topical melatonin for hair loss treatment. The user is considering making their own solution and is unsure whether a higher concentration is more effective for deactivating prolactin receptors.